Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Datamonitor Healthcare Reports | Stakeholder Opinions: Pancreatic Cancer - Gemzar dominance will continue among high levels of persistent unmet needs

Stakeholder Opinions: Pancreatic Cancer - Gemzar dominance will continue among high levels of persistent unmet needs

Only 15-20% of pancreatic cancer patients have resectable disease, therefore most receive systemic therapy. Gemzar (gemcitabine; Eli Lilly) forms the current standard of care for advanced disease. Despite this, no treatment is truly effective, with five-year survival at 5% for all stages of disease. Significant unmet needs therefore remain, with ample commercial opportunities for drug developers.

Scope

*Pancreatic cancer overview, including definition, risk factors, epidemiology forecasts and discussion of unmet needs

*Current diagnosis and treatment of pancreatic cancer, including drug regimens used by stage and ongoing controversies

*Examination of the late-phase pancreatic cancer pipeline and market opportunities for drug developers

*Stakeholder opinions based on qualitative interviews with key opinion leaders in the field of pancreatic cancer

Highlights

Gemzar is the current standard of care for unresectable locally advanced and metastatic pancreatic cancer. Despite this, Gemzar is only associated with median overall survival of 5.7 months and a one-year survival rate of 18%. It is therefore clear that treatment of pancreatic cancer continues to be plagued by high levels of unmet need.

Other lines of therapy in pancreatic cancer remain ill defined due to a lack of definitive randomized clinical trial data. Controversy persists regarding the use of neoadjuvant versus adjuvant therapy, while the role of radiotherapy alongside chemotherapy in these settings continues to provoke debate.

The pancreatic cancer pipeline is relatively active, with six Phase III agents. Despite this, Gemzar is set to retain its leading status for the foreseeable future. While promising Phase II results have been shown, this has yet to be translated into Phase III efficacy. As a result, no pipeline agent has yet shown the potential to replace Gemzar.

Reasons to Purchase

*Identify the limitations of current therapy available to pancreatic cancer patients and the potential of future therapy

*Understand current epidemiological trends in pancreatic cancer and ongoing treatment controversies

*Assess the opportunities for innovative targeted therapies in the pancreatic cancer market, particularly in metastatic disease

12-Mar-09 PDF & SlidePack Pages 89

Table of Contents
Price: $3,800.00 / €2,539.92

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions